Information Provided By:
Fly News Breaks for January 18, 2018
TEVA, MYL, IPXL, ENDP
Jan 18, 2018 | 11:19 EDT
Cantor Fitzgerald analyst Louise Chen said that concerns about hospitals possibly manufacturing their own generic drugs, spurred by a New York Times article discussing the subject, are overdone. Generics companies who responded to the analyst noted that sterile manufacturing is very difficult and drug approvals and plant inspections take time, so any opportunity for hospitals is likely many years away at best, unless they decided to acquire a company, said Chen. The analyst, who said the headlines are "just noise," has Neutral ratings on Endo (ENDP), Mylan (MYL) and Teva (TEVA) and an Overweight rating on Impax (IPXL).
News For ENDP;IPXL;MYL;TEVA From the Last 2 Days
There are no results for your query ENDP;IPXL;MYL;TEVA